<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tonix Pharmaceuticals Holding Corp. — News on 6ix</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp</link>
<description>Latest news and press releases for Tonix Pharmaceuticals Holding Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tonix-pharmaceuticals-holding-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb1d78dffbe2df11d055.webp</url>
<title>Tonix Pharmaceuticals Holding Corp.</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp</link>
</image>
<item>
<title>Tonix Pharmaceuticals to Participate in Two Investor Conferences in May</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-participate-in-two-investor-conferences-in-may</guid>
<pubDate>Tue, 12 May 2026 20:30:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026. RBC Capital Markets Global Healthcare ConferenceFireside ChatParticipant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: New York, New YorkDate: May 19, 202</description>
</item>
<item>
<title>Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-highlights</guid>
<pubDate>Mon, 11 May 2026 20:30:00 GMT</pubDate>
<description>In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading group purchasing organization (GPO) that provides access to TONMYA for approximately 35 million U.S. commercial lives Expect to initiate adaptive Phase 2 field study for the prevention of Lyme disease in the U.S. in the first half of 2027 for TNX-4800, pending FDA agreement Approximately $185.5 million</description>
</item>
<item>
<title>Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-secures-commercial-payer-coverage-for-tonmyar-providing-access-for-35-million-us-patients</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-secures-commercial-payer-coverage-for-tonmyar-providing-access-for-35-million-us-patients</guid>
<pubDate>Wed, 06 May 2026 11:00:00 GMT</pubDate>
<description>Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine HCl sublingual tablets), the first FDA-approved treatment for fibromyalgia in adults in more than 15 years, commercially launched in November 2025 TONMYA is a first-in-class non-opioid analgesic indicated for the treatment of fibromyalgia in adults as a daily bedtime medicine for long-term use BERKE</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-plans-for-an-adaptive-phase-2-field-study-of-tnx-4800-anti-borrelia-ospa-monoclonal-antibody-for-the-prevention-of-lyme-disease-at-the-4th-annual-ticks-and-tickborne-diseases-symposium-at-johns-hopkins-university</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-plans-for-an-adaptive-phase-2-field-study-of-tnx-4800-anti-borrelia-ospa-monoclonal-antibody-for-the-prevention-of-lyme-disease-at-the-4th-annual-ticks-and-tickborne-diseases-symposium-at-johns-hopkins-university</guid>
<pubDate>Wed, 29 Apr 2026 11:00:00 GMT</pubDate>
<description>Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreement Phase 2 field study expected to test a two-dose regimen of TNX-4800 subcutaneous with an initial Spring dose followed by a Summer booster two months later; the primary endpoint is Lyme disease prevention for six months TNX-4800 is expected to provide protection against Lyme disease within two days of the first dose for the peak of the U.S. Lym</description>
</item>
<item>
<title>Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models TNX-1700 exhibited dose-independent, linear pharmacokinetics in animals TNX-4700 (human anti-BTLA monoclonal antibody) demonstrated potent, high-affinity binding and functional antagonism BERKELEY HEIGHTS, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or th</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmyar-after-20-days-of-daily-dosing-in-the-peer-reviewed-journal-clinical-pharmacology-in-drug-development</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmyar-after-20-days-of-daily-dosing-in-the-peer-reviewed-journal-clinical-pharmacology-in-drug-development</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-outlines-planned-adaptive-phase-2-field-study-of-tnx-4800-for-the-prevention-of-lyme-disease-at-the-world-vaccine-congress-washington-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentation-of-phase-1-data-and-outlines-planned-adaptive-phase-2-field-study-of-tnx-4800-for-the-prevention-of-lyme-disease-at-the-world-vaccine-congress-washington-2026</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-first-participant-dosed-in-phase-1-investigator-initiated-pharmacodynamic-study-of-tnx-1900-intranasal-potentiated-oxytocin-to-assess-potential-for-treating-migraine-and-craniofacial-pain</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-first-participant-dosed-in-phase-1-investigator-initiated-pharmacodynamic-study-of-tnx-1900-intranasal-potentiated-oxytocin-to-assess-potential-for-treating-migraine-and-craniofacial-pain</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentations-at-world-vaccine-congress-washington-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-presentations-at-world-vaccine-congress-washington-2026</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday,</description>
</item>
<item>
<title>Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-present-at-bio-europe-spring-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-present-at-bio-europe-spring-2026</guid>
<pubDate>Wed, 18 Mar 2026 20:58:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal. Company Presentation Details Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WETLocation: Presentation Theatre APresenter:</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-oral-presentation-and-two-poster-presentations-on-preclinical-immuno-oncology-portfolio-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-oral-presentation-and-two-poster-presentations-on-preclinical-immuno-oncology-portfolio-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated,</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-7</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-7</guid>
<pubDate>Fri, 13 Mar 2026 12:35:00 GMT</pubDate>
<description>NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging tec</description>
</item>
<item>
<title>Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
<pubDate>Thu, 12 Mar 2026 21:30:00 GMT</pubDate>
<description>TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to patients, approximately 2,500 patients have initiated treatment with TONMYA, and cumulative prescriptions totaled approximately 4,200 Expect to initiate U.S. field study in 2027 for TNX-4800 for seasonal prevention of Lyme disease pending FDA clearance Completed $20.0 million registered direct off</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-2</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-2</guid>
<pubDate>Tue, 10 Mar 2026 14:21:00 GMT</pubDate>
<description>Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the on</description>
</item>
<item>
<title>Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-post-hoc-analyses-of-phase-3-data-on-tonmyatm-at-the-8th-international-congress-on-controversies-in-fibromyalgia</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-post-hoc-analyses-of-phase-3-data-on-tonmyatm-at-the-8th-international-congress-on-controversies-in-fibromyalgia</guid>
<pubDate>Tue, 10 Mar 2026 12:00:00 GMT</pubDate>
<description>Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary endpoints as compared to placebo In pooled post hoc analysis of the pivotal RELIEF and RELISIENT studies, TONMYA showed favorable benefit-risk profile using number needed to treat, number needed to harm, and</description>
</item>
<item>
<title>Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-data-on-tonmyatm-in-treating-patients-with-fibromyalgia-at-the-2026-aapm-painconnect-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-data-on-tonmyatm-in-treating-patients-with-fibromyalgia-at-the-2026-aapm-painconnect-annual-meeting</guid>
<pubDate>Mon, 09 Mar 2026 20:30:00 GMT</pubDate>
<description>TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, presented data on TONMYATM (cyclobenzaprine H</description>
</item>
<item>
<title>Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-data-on-tonmyatm-in-treating-patients-with-fibromyalgia-at-the-2026-aapm-painconnect-annual-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-presented-data-on-tonmyatm-in-treating-patients-with-fibromyalgia-at-the-2026-aapm-painconnect-annual-meeting-1</guid>
<pubDate>Mon, 09 Mar 2026 20:30:00 GMT</pubDate>
<description>TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well toleratedBERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, presented data on TONMYA™ (cyclobenzaprine HCl</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-publication-of-clinical-pharmacokinetic-studies-of-tonmyatm-and-prototype-formulations-in-the-journal-clinical-pharmacology-in-drug-development-65</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-publication-of-clinical-pharmacokinetic-studies-of-tonmyatm-and-prototype-formulations-in-the-journal-clinical-pharmacology-in-drug-development-65</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new</description>
</item>
<item>
<title>Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-present-poster-on-tonmyatm-at-the-2026-american-academy-of-pain-medicine-painconnect-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-to-present-poster-on-tonmyatm-at-the-2026-american-academy-of-pain-medicine-painconnect-annual-meeting</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, being held March 5–8, 2026, in Salt Lake City, Utah. A copy of the Company’s presentation will be</description>
</item>
<item>
<title>Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market</title>
<link>https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-uplisting-from-nasdaq-capital-market-to-nasdaq-global-select-market</link>
<guid isPermaLink="true">https://6ix.com/company/tonix-pharmaceuticals-holding-corp/news/tonix-pharmaceuticals-announces-uplisting-from-nasdaq-capital-market-to-nasdaq-global-select-market</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated,</description>
</item>
</channel>
</rss>